PBLA Stock Price, Panbela Therapeutics . Quote, Chart

Market Summary

USD0.44-0.04

Delayed

-8.33%

PBLA Stock Price

View Fullscreen

PBLA RSI Chart

PBLA Valuation

Market Cap

2.1M

Price/Earnings (Trailing)

-0.08

Price/Sales (Trailing)

2.1K

EV/EBITDA

-0.19

Price/Free Cashflow

-0.09

PBLA Price/Sales (Trailing)

PBLA Profitability

Operating Margin

-48652.00%

EBT Margin

-2758750.00%

Return on Equity

851.81%

Return on Assets

-258.93%

Free Cashflow Yield

-1.2K%

PBLA Fundamentals

PBLA Revenue

Revenue (TTM)

1.0K

PBLA Earnings

Earnings (TTM)

-27.3M

Earnings Growth (Yr)

-38.93%

Earnings Growth (Qtr)

-9.98%

Breaking Down PBLA Revenue

Last 7 days

-60.4%

Last 30 days

-15.4%

Last 90 days

-64.8%

Trailing 12 Months

-96.3%

How does PBLA drawdown profile look like?

PBLA Financial Health

Current Ratio

0.17

Debt/Equity

-1

Debt/Cashflow

-7.8

PBLA Investor Care

Shares Dilution (1Y)

17252.40%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2018	0	0	0	0
2017	0	3.0K	2.0K	1.0K
2016	7.0K	5.0K	5.0K	4.0K
2015	0	0	0	8.0K
2014	0	0	0	0
2013	1.2M	1.1M	1.0M	973.8K
2012	0	0	0	1.2M
2011	0	0	0	699.8K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Panbela Therapeutics Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 08, 2023	goldman sachs group inc	sold	-51,740	0.71	-72,874	-
Sep 12, 2023	jacob jeffrey e.	gifted	-	-	-275	-
Jan 30, 2023	simpson jennifer k.	bought	-	-	4,444	president and ceo
Jan 30, 2023	horvath susan	bought	-	-	4,444	v.p. of finance & cfo
Oct 04, 2022	jacob jeffrey e.	bought	-	-	33,000	-
Oct 04, 2022	cullen michael t.	bought	-	-	165,000	-
Oct 04, 2022	schemel donald robert	bought	-	-	200,000	-
May 25, 2021	mathiesen jeffrey s	acquired	-	-	4,316	-
May 25, 2021	cullen michael t.	acquired	-	-	4,316	-
May 25, 2021	schemel donald robert	acquired	-	-	4,316	-

Which funds bought or sold PBLA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-31,303	-	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-448,588	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-10,695	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-13,739	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-2.00	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-9.00	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	sold off	-100	-14,535	-	-%
May 13, 2024	HRT FINANCIAL LP	sold off	-100	-34,000	-	-%
May 10, 2024	JPMORGAN CHASE & CO	sold off	-100	-11,393	-	-%
May 10, 2024	OSAIC HOLDINGS, INC.	sold off	-100	-63.00	-	-%

Are Funds Buying or Selling PBLA?

Are funds buying PBLA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PBLA

No. of Funds

Unveiling Panbela Therapeutics Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	lind global fund ii lp	0%	0	SC 13G/A
Feb 14, 2023	cullen michael t.	3.3%	35,053	SC 13G/A
Jan 30, 2023	lind global fund ii lp	9.9%	590,000	SC 13G
Feb 14, 2022	cullen michael t.	6.3%	873,318	SC 13G/A

Recent SEC filings of Panbela Therapeutics Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	424B3	Prospectus Filed
May 16, 2024	424B3	Prospectus Filed
May 16, 2024	424B3	Prospectus Filed
May 16, 2024	424B3	Prospectus Filed
May 16, 2024	424B3	Prospectus Filed
May 16, 2024	424B3	Prospectus Filed
May 16, 2024	424B3	Prospectus Filed
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 06, 2024	DEFR14A	DEFR14A

Peers (Alternatives to Panbela Therapeutics Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Panbela Therapeutics Inc. News

Latest updates

Panbela Therapeutics Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2
Revenue	141.7%	29.00	12.00	10.00	34.00	59.00	83.00	42.00	-	1.00	1.00	3.00	-	3.00	99.00	195	291	296	300	305	246	204
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	142	146	58.00	142	154	241	-107	230	222
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	149	141	455	150	155	1.00	405	16.00	-3.51
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	418	70.00	40.00
S&GA Expenses	-28.6%	467	654	658	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	1.8%	450	442	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-99.8%	3.00	1,288	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	30.4%	-55.00	-79.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	61.8%	-980	-2,564	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	62.8%	-925	-2,487	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.8%	10,527	11,802	10,628	19,551	16,475	4,978	4,867	6,557	11,088	12,872	14,802	7,295	8,894	9,813	11,485	3,322	2,136	3,144	3,820	1,339	1,911
Current Assets	-41.7%	1,785	3,060	1,886	10,809	7,833	1,777	1,766	3,456	7,933	12,279	14,749	7,240	8,839	9,757	11,433	3,272	2,091	3,093	3,771	1,288	1,860
Cash Equivalents	-89.9%	262	2,600	900	7,200	5,235	1,285	941	2,530	7,400	11,867	14,072	6,405	8,098	9,022	10,870	2,265	1,296	2,449	3,377	721	1,379
Liabilities	-17.0%	13,713	16,512	13,111	14,749	13,940	13,027	13,146	11,395	7,028	2,660	2,336	2,013	1,689	1,365	-	-	-	1,759	1,431	1,456	1,543
Current Liabilities	-14.6%	10,519	12,318	8,917	10,555	9,746	7,833	7,952	6,201	4,507	2,660	1,339	1,393	1,310	1,365	1,936	1,722	1,412	1,759	689	714	2,499
Long Term Debt	-23.8%	3,194	4,194	4,194	4,194	4,194	5,194	5,194	5,194	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	232	259
LT Debt, Non Current	-100.0%	-	4,194	4,194	4,194	4,194	5,194	5,194	5,194	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	32.1%	-3,200	-4,710	-	4,796	2,525	-8,049	-	-	6,582	10,213	13,463	5,889	7,584	8,447	9,549	1,600	724	1,384	2,389	-	-
Retained Earnings	-5.7%	-132,617	-125,500	-109,900	-102,046	-96,207	-91,094	-86,359	-82,000	-59,800	-56,161	-52,600	-50,500	-48,283	-46,026	-45,146	-43,475	-43,056	-41,258	-40,284	-38,910	-36,639
Additional Paid-In Capital	6.8%	128,223	120,043	106,026	105,855	97,804	82,286	76,686	76,451	66,561	66,240	65,891	56,506	56,142	54,848	54,544	44,681	42,671	42,331	42,164	38,487	35,795
Shares Outstanding	911.4%	4,855	480	150	131	27.00	2.00	855.35*	600.15*	560.02*	10.00	463.45*	420.54*	411.98*	402.68*	-	-	-	-	-	-	-
Float	-	-	-	-	6,004	-	-	-	11,426	-	-	-	33,799	-	-	-	30,196	-	-	-	9,496	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-205.2%	-9,400	-3,080	-6,677	-5,741	-9,751	-5,003	-1,593	-4,197	-4,483	-2,228	-1,359	-1,693	-1,965	-1,113	-765	-856	-1,120	-872	-453	-631	-783
Share Based Compensation	-16.9%	103	124	190	329	180	231	230	293	334	336	335	364	252	236	593	264	112	135	536	412	10.00
Cashflow From Investing	-	-	-	400	-	-	-	-1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	49.3%	7,082	4,742	-	7,700	13,700	5,349	5.00	-	-	1.00	9,053	-	1,042	-711	9,359	1,822	-26.00	-61.00	3,115	-28.00	758

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PBLA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
General and administrative	$ 1,204	$ 1,352
Research and development	5,522	3,508
Operating loss	(6,726)	(4,860)
Other income (expense):
Interest income	0	16
Interest expense	(63)	(102)
Other expense	(469)	(167)
Total other expense	(532)	(253)
Loss before income tax benefit	(7,258)	(5,113)
Income tax benefit	138	0
Net loss	(7,120)	(5,113)
Foreign currency translation adjustment	459	163
Comprehensive loss	$ (6,661)	$ (4,950)
Basic and diluted net loss per share (in dollars per share)	$ (2.28)	$ (392.76)
Weighted average shares outstanding - basic and diluted (in shares)	3,125,835	13,018

PBLA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 262,000	$ 2,578,000
Prepaid expenses and other current assets	1,210,000	299,000
Income tax receivable	313,000	183,000
Total current assets	1,785,000	3,060,000
Other non-current assets	8,742,000	8,742,000
Total assets	10,527,000	11,802,000
Current liabilities:
Accounts payable	8,506,000	9,939,000
Accrued expenses	979,000	1,141,000
Accrued interest payable	34,000	238,000
Debt, current portion	1,000,000	1,000,000
Total current liabilities	10,519,000	12,318,000
Debt, net of current portion	3,194,000	4,194,000
Total non-current liabilities	3,194,000	4,194,000
Total liabilities	13,713,000	16,512,000
Stockholders' deficit:
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 4,854,931 and 480,095 issued as of March 31, 2024 and December 31, 2023 respectively; 4,854,861 and 480,025 shares outstanding as of March 31, 2024 and December 31, 2023, respectively	5,000	0
Treasury Stock at cost; 70 shares at both of March 31, 2024 and December 31, 2023	(1,000)	(1,000)
Additional paid-in capital	128,223,000	120,043,000
Accumulated deficit	(132,617,000)	(125,497,000)
Accumulated comprehensive income	1,204,000	745,000
Total stockholders' deficit	(3,186,000)	(4,710,000)
Total liabilities and stockholders' deficit	$ 10,527,000	$ 11,802,000

About Panbela Therapeutics Inc.

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with cancer. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin (SBP-101). The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

CEO	Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D.
WEBSITE	panbela.com
INDUSTRY	Biotechnology
EMPLOYEES	6

Panbela Therapeutics Inc. Frequently Asked Questions

What is the ticker symbol for Panbela Therapeutics Inc.? What does PBLA stand for in stocks?

PBLA is the stock ticker symbol of Panbela Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Panbela Therapeutics Inc. (PBLA)?

As of Fri May 17 2024, market cap of Panbela Therapeutics Inc. is 2.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PBLA stock?

You can check PBLA's fair value in chart for subscribers.

What is the fair value of PBLA stock?

You can check PBLA's fair value in chart for subscribers. The fair value of Panbela Therapeutics Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Panbela Therapeutics Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PBLA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Panbela Therapeutics Inc. a good stock to buy?

The fair value guage provides a quick view whether PBLA is over valued or under valued. Whether Panbela Therapeutics Inc. is cheap or expensive depends on the assumptions which impact Panbela Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PBLA.

What is Panbela Therapeutics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PBLA's PE ratio (Price to Earnings) is -0.08 and Price to Sales (PS) ratio is 1.94 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PBLA PE ratio will change depending on the future growth rate expectations of investors.